Total Pharmacy Interviews

Matt Sample from Cencora discusses current DSCSA developments on the rise for pharmacy businesses in 2026—namely small dispensers that have been under exemption.

In this episode, host Taylor Watterson, PharmD, PhD, welcomes Mohammad Al Numan, BS, MS, a 2025-27 University of Illinois Chicago/Takeda Fellow in Health Economics and Outcomes Research.

Direct contracting can boost transparent drug pricing and help independent pharmacies earn fairly while patients save on generic medications.

As the pharmacy industry seemingly transforms in real-time, expert pharmacists and digital health experts explain how DTP models are paving a new path for drug distribution.

Timothy Aungst, PharmD; Ravi Patel, PharmD, MBA, MS; and Smit Patel, PharmD; provided much-needed nuance to the evolving nature of DTP pharmacy models in today’s landscape.

Timothy Aungst, PharmD; Ravi Patel, PharmD, MBA, MS; and Smit Patel, PharmD, share their insights on the emerging direct-to-patient pharmacy model.

Anne Cassity, senior vice president of government affairs at NCPA, discusses the next moves of both PBMs and community pharmacy advocates following the signing of HR 7148.

With President Trump’s signing of HR 7148, experts are now racing to get a grasp on the monumental shifts in pharmacy that will stem from this new legislation.

As lawmakers continue to deliberate on HR 7148, pharmacy law expert, Jesse Dresser, Esq, joined Drug Topics to discuss its provisions related to PBMs.

If signed by President Trump in time to avoid a government shutdown, HR 7148 has potential to enforce significant change in the prescription drug supply chain.

As more prescription drugs move to OTC, the pharmacist’s role in their communities are continuing to shift as well.

In part 2, Alyssa Billingsley, PharmD, explores some of the recent switches that made waves in the US and how they impact pharmacy operations as well as patient outcomes.

Community pharmacies continue to operate in unchartered territory regarding Medicare drug price negotiations as the new IRA statute becomes an unavoidable reality for business operations.

With unprecedented changes to Medicare Part D plans at the top of the year, experts from ASCP help pharmacy businesses understand key provisions under the IRA.

Representatives from the American Society of Consultant Pharmacists joined Drug Topics to discuss the day 1 reality of the Medicare Drug Price Negotiation Program.

To celebrate National Pharmacist Day, regonized every year on January 12, Meagan Brown, PharmD, BCACP, discussed the current state of nationally recognizing pharmacists as clinical providers.

Meagan Brown, PharmD, BCACP, discusses the nuances of pharmacists’ provider status and its evolution within the greater health care community.

Meagan Brown, PharmD, BCACP, discusses her career journey in various pharmacy roles during National Pharmacist Day, January 12.

From gaps in care to formulary challenges, Susan Thomas, RN, explains how her independent PBM is working with pharmacists to improve women’s health outcomes.

As social media’s growth seemingly has no end in sight, pharmacists must be conscious of its potential risks and benefits when using these platforms for either personal or professional use.

Discover how pharmacy teams are advancing stewardship, opioid safety, and survey readiness through clinical surveillance, competency-based education, and emerging AI tools that help reduce ADEs and improve patient outcomes.

Ron Lanton III, Esq, provides nuance to the current state of pharmacy sustainability and how the MFN drug pricing policy could impact the industry.

Ron Lanton III, Esq, discusses previous MFN drug pricing policies and why the free US drug market often yields higher patient costs.

Ron Lanton III, Esq, discusses the revamped version of the Trump Administration’s MFN drug pricing policy and why his second term may yield different outcomes.

From the COVID-19 pandemic through state-by-state expansion of scope, pharmacists have tapped into a variety of their clinical skills to bolster patient outcomes in their communities.

With the constant financial hurdles businesses face, the community pharmacy industry has struggled with finding new ways to innovate within its practices.

With disruptive PBMs rising in the marketplace amid constant calls for lowering drug prices, companies such as WriteWise are positioned to revolutionize the way patients access their pharmacy benefits.

In part 3 of our interview with Bill Wolfe, COO of WriteWise, he discusses the technology backing his team’s approach to forever changing how pharmacy benefits are distributed in the US.

Bill Wolfe, COO at WriteWise and former President of Aetna’s Pharmacy Management team, discusses the evolution of pharmacy benefits and where PBM and pharmacist roles fall in between.

Pharmacists are actively working to increase public awareness and acceptance of their expanded health care role through advocacy for legislative changes that recognize their critical contributions to patient care.